FDA Approves YARTEMLEA as First Therapy for Life-Threatening Transplant Complication TA-TMA
核心洞察
The FDA has approved YARTEMLEA (搜索) (narsoplimab-wuug (搜索)) as the first and only therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (搜索) (TA-TMA (搜索)), a severe complication affecting up to 56% of transplant recipients.
Clinical trials demonstrated a 61% complete response rate in the pivotal study and 73-74% 100-day survival rates, representing a three- to fourfold reduction in mortality risk compared to external controls.
The monoclonal antibody selectively inhibits MASP-2 (搜索), the effector enzyme of the lectin pathway (搜索) of complement, while preserving other immune functions essential for host defense.
The U.S. Food and Drug Administration has approved YARTEMLEA (搜索) (narsoplimab-wuug (搜索)) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (搜索) (TA-TMA (搜索)), marking the first approved therapy for this often-fatal complication of stem cell transplantation. The approval represents a significant breakthrough for patients facing a condition with mortality rates that can exceed 90% in severe cases.
Breakthrough Approval Based on Robust Clinical Data
The FDA approval was based on results from a single-arm, open-label study in 28 adults with TA-TMA (搜索), supported by additional data from an expanded access program involving 221 adult and pediatric patients. In the pivotal study, 17 of 28 patients (61%) achieved a complete response, defined as improvement in key laboratory markers including platelet counts and LDH levels, together with either improved organ function or transfusion independence.
The expanded access program provided additional validation, with 13 of 19 evaluable patients (68%) achieving complete response. Across both studies, 100-day survival from the time of TMA diagnosis was 73% (95% CI: 52, 86) in the pivotal study and 74% (95% CI: 48, 88) in the expanded access program.
"This approval is a long-awaited breakthrough in hematopoietic cell transplantation and TA-TMA (搜索) care," stated Miguel-Angel Perales, M.D., Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center. "Until now, we've lacked an effective TA-TMA therapy and relied largely on supportive measures such as modifying calcineurin inhibitors, which can significantly increase the risk of life-threatening graft-versus-host disease (搜索)."
Superior Survival Outcomes in High-Risk Patients
Peer-reviewed publications demonstrated that treatment with YARTEMLEA (搜索) was associated with a three- to fourfold lower risk of mortality compared with an external control cohort. In previously refractory high-risk patients who had failed or discontinued prior regimens including off-label complement inhibitors and defibrotide, YARTEMLEA was associated with 50% one-year survival, compared with historical one-year survival rates reported as less than 20%.
All patients in the studies met international harmonization criteria for high-risk TA-TMA (搜索), classifying each as having a poor prognosis and high risk of death. The drug was used both as first-line therapy and in patients who had failed previous treatments.
Pediatric Applications Show Promise
The approval extends to children ages two years and older, addressing a critical unmet need in pediatric transplantation. Michelle Schoettler, M.D., Assistant Professor of Pediatric Oncology and Hematopoietic Cellular Therapy at Emory University, emphasized the significance for pediatric patients.
"When used first-line, YARTEMLEA (搜索) has been associated with approximately 75% one-year survival; and even in children refractory to one or more off-label complement inhibitors, one-year survival is approximately triple historical rates that have remained below 20%," Schoettler noted. "With this approval, effective TA-TMA (搜索) therapy can become the pediatric standard instead of the exception."
Novel Mechanism of Action
YARTEMLEA (搜索) is a fully human monoclonal antibody that represents the first and only approved inhibitor of the lectin pathway (搜索) of complement. The drug selectively inhibits mannan-binding lectin-associated serine protease-2 (搜索) (MASP-2 (搜索)), the effector enzyme of the lectin pathway, preventing lectin pathway-mediated cellular injury including endothelial damage in small blood vessels and thrombus formation.
Importantly, by selectively blocking activation of the lectin pathway (搜索), YARTEMLEA (搜索) preserves classical and alternative pathway activity, including functions essential to the adaptive immune response and host defense.
Safety Profile and Clinical Considerations
The most common adverse reactions (≥20%) observed in clinical trials were viral infections, sepsis, hemorrhage, diarrhea, vomiting, nausea, neutropenia, pyrexia, fatigue, and hypokalemia. Serious adverse reactions occurred in 61% of patients, with those reported in more than 5% including acute kidney injury, confusional state, acute respiratory failure, neutropenic sepsis, septic shock, pulmonary edema, and vomiting.
Fatal adverse reactions were reported in 7% of patients, including neutropenic sepsis and septic shock. Serious infections were reported in 36% of patients receiving YARTEMLEA (搜索), including sepsis, viral infections, pneumonia, bacteremia, and fungal infections.
Addressing a Critical Medical Need
TA-TMA (搜索) is driven by systemic endothelial injury triggered by conditioning regimens, immunosuppressants, infection, graft-versus-host disease (搜索), and other transplant-related factors, with activation of the lectin pathway (搜索) of complement playing a central role in disease pathogenesis. The condition can occur following both autologous and allogeneic transplant, with higher prevalence after allogeneic procedures.
Approximately 30,000 allogeneic transplants are performed annually in the U.S. and Europe, with recent studies estimating that TA-TMA (搜索) develops in up to 56% of allogeneic transplant recipients. Survivors frequently face long-term renal complications, including dialysis dependence.
Commercial Launch and Global Expansion
Omeros Corporation is finalizing preparations for its U.S. product launch planned for January 2026. Dedicated billing and reimbursement codes are now in place, including ICD-10-CM code M31.11 specific to the diagnosis of TA-TMA (搜索) and procedure codes for narsoplimab administration.
A marketing authorization application for YARTEMLEA (搜索) is currently under review by the European Medicines Agency (搜索), with a decision expected in mid-2026. The drug has received breakthrough therapy and orphan drug designations from the FDA for TA-TMA (搜索), and the EMA has granted orphan drug designation in hematopoietic stem-cell transplantation.
"After years of work and close collaboration with the transplant community, we can now offer the first FDA-approved therapy for this frequently fatal complication, with robust response data and a benefit-risk profile that supports confident use in both adults and children," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.